Investor Relations Investor Center Stock Information Financial Information Corporate Governance Press Releases Events & Presentations Investor FAQ Contact Us
Press Releases Year None20262025202420232022202120202019201820172016201520142013201220112010200920082007 May 13, 2026 Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update PDF Version Apr 15, 2026 Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B PDF Version Mar 23, 2026 Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update PDF Version Mar 03, 2026 Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna PDF Version Shareholder Tools Email Alerts Email Alerts RSS News Feeds RSS News Feeds Download Library Download Library
Press Releases Year None20262025202420232022202120202019201820172016201520142013201220112010200920082007 May 13, 2026 Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update PDF Version Apr 15, 2026 Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B PDF Version Mar 23, 2026 Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update PDF Version Mar 03, 2026 Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna PDF Version
May 13, 2026 Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update PDF Version
Apr 15, 2026 Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B PDF Version
Mar 23, 2026 Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update PDF Version
Mar 03, 2026 Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna PDF Version
